Innovations and challenges in renal cell carcinoma: Summary statement from the second Cambridge conference

被引:32
作者
Atkins, Michael B.
Ernstoff, Marc S.
Figlin, Robert A.
T Flaherty, Keith
George, Daniel J.
Kaelin, William G., Jr.
Kwon, Eugene D.
Libermann, Towia A.
Linehan, W. Marston
McDermott, David F.
Ochoa, Augusto C.
Pantuck, Allan J.
Rini, Brian I.
Rosen, Mark A.
Sosman, Jeffrey A.
Sukhatme, Vikas P.
Vieweg, Johannes W.
Wood, Christopher G.
King, Laura
机构
[1] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA
[2] Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA
[3] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA USA
[4] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA
[5] Univ Penn, Med Ctr, Philadelphia, PA 19104 USA
[6] Univ Florida, Hlth Sci Ctr, Gainesville, FL USA
[7] Howard Hughes Med Inst, Dana Farber Canc Inst, Boston, MA 02115 USA
[8] Mayo Clin, Rochester, MN USA
[9] NCI, Bethesda, MD 20892 USA
[10] Louisiana State Univ, Hlth Sci Ctr, New Orleans, LA USA
[11] Cleveland Clin, Taussig Canc Ctr, Cleveland, OH 44106 USA
[12] Vanderbilt Ingram Canc Ctr, Nashville, TN USA
[13] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
[14] InforMED Commun Inc, Carlisle, MA USA
关键词
D O I
10.1158/1078-0432.CCR-06-2231
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Innovations and Challenges in Renal Cancer, chaired by Michael B. Atkins, was held April 28 to 29, 2006 in Cambridge, Massachusetts. The conference brought together leading experts in the fields of cancer research, medical oncology, urology, immunology, radiology, and immunotherapy, with the goal of advancing the field of renal cancer treatment by critiquing new data from ongoing clinical trials and stimulating communication among those involved in basic and clinical research. The conference proceedings published in this educational supplement to Clinical Cancer Research are intended to provide timely information and recommendations on important aspects of renal cancer genetics and biology and advances in prognostic classification and treatment.
引用
收藏
页码:667S / 670S
页数:4
相关论文
共 10 条
  • [1] Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma
    Atkins, MB
    Hidalgo, M
    Stadler, WM
    Logan, TF
    Dutcher, JP
    Hudes, GR
    Park, Y
    Lion, SH
    Marshall, B
    Boni, JP
    Dukart, G
    Sherman, ML
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (05) : 909 - 918
  • [2] ESCUDIER B, 2005, P AN M AM SOC CLIN, V23, P4510
  • [3] Hudes G, 2006, J CLIN ONCOL, V24, p2S
  • [4] Focus on kidney cancer
    Linehan, WM
    Zbar, B
    [J]. CANCER CELL, 2004, 6 (03) : 223 - 228
  • [5] Motzer RJ, 2006, J CLIN ONCOL, V24, p930S
  • [6] Motzer R. J., 2005, J. Clin. Oncol, V23, P4508, DOI [10.1200/jco.2005.23.16_suppl.4508, DOI 10.1200/JCO.2005.23.16_SUPPL.4508]
  • [7] Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma
    Motzer, RJ
    Michaelson, MD
    Redman, BG
    Hudes, GR
    Wilding, G
    Figlin, RA
    Ginsberg, MS
    Kim, ST
    Baum, CM
    DePrimo, SE
    Li, JZ
    Bello, CL
    Theuer, CP
    George, DJ
    Rini, BI
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (01) : 16 - 24
  • [8] N. C. I. (NCI), CANC STAT FACT SHEET
  • [9] Cancer immunotherapy: moving beyond current vaccines
    Rosenberg, SA
    Yang, JC
    Restifo, NP
    [J]. NATURE MEDICINE, 2004, 10 (09) : 909 - 915
  • [10] Tabernero J, 2005, P AN M AM SOC CLIN, V23, P3007